ArticleBMJ open2020
Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study.
Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research.CNS drugs · 2022Pooled it
- Second-Generation Antipsychotics for Depression in Serious Illness: A First-Line Augmentation Strategy.Journal of pain and symptom management · 2026Review
- Prevalence of chronic kidney disease in people with severe mental illness: systematic review and meta-analysis.The British journal of psychiatry : the journal of mental science · 2026Review
- Mental health and kidney disease.Nature reviews. Nephrology · 2026Review
- Lithium nephrotoxicity: a systematic review and meta-analysis of lithium versus non-lithium control studies in patients with affective disorders.Therapeutic advances in psychopharmacology · 2026Review
- Antioxidant Supplementation with ProCloSupp Protects Against Renal Toxicity of Atypical Antipsychotics in Rats: Implications for Safer Treatment Strategies.Life (Basel, Switzerland) · 2025Article
- Relationship between renal function and cognitive impairment in patients with stable schizophrenia: a multicenter cross-sectional study.BMC psychiatry · 2025Article
- Albuminuria and Mental Illness Risk: Results From National Health and Nutrition Examination Survey 2005-2018 and Mendelian Randomization Analyses.Brain and behavior · 2025Article
- The prevalence of chronic kidney disease in people with severe mental illness: A systematic review protocol.PloS one · 2025Article
- Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study.International journal of bipolar disorders · 2023Article
- Anti-Inflammatory Effects of Peripheral Dopamine.International journal of molecular sciences · 2023Review
- Chronic kidney disease and severe mental illness: a scoping review.Journal of nephrology · 2023Article
- Non-traditional risk factors of progression of chronic kidney disease in adult population: a scoping review.Frontiers in medicine · 2023Article
- National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era.Schizophrenia research · 2022Article
- Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study.European journal of clinical pharmacology · 2022Article
- Lithium and the risk of chronic kidney disease: A population-based case-control study.Basic & clinical pharmacology & toxicology · 2022Article
- The Effects of Use of Long-Term Second-Generation Antipsychotics on Liver and Kidney Function: A Prospective Study.Diseases (Basel, Switzerland) · 2022Article
- Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice.International journal of molecular sciences · 2021Article
- Physical health examination in outpatients with schizophrenia: the cost effectiveness of laboratory screening tests.Annals of general psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the association between use of second-generation antipsychotics (SGA) and the risk of chronic kidney disease (CKD).
designPopulation-based case-control study.
settingRoutinely collected laboratory, prescription and diagnostic information on all inhabitants with creatinine measurements residing on the island of Funen, Denmark (2001 to 2015).
participants21 434 cases with incident CKD matched with 85 576 CKD-free population controls by risk-set sampling using age, sex and calendar year. PRIMARY AND SECONDARY OUTCOME MEASURES: CKD was defined as an estimated glomerular filtration rate below 60 mL/min/1.73 m
resultsUse of SGAs was associated with increased risk of CKD among ever users (OR 1.24, 95% CI: 1.12 to 1.37) and current users (OR 1.26, 95% CI: 1.12 to 1.42). We found no clear evidence of dose-response relationship. Both short duration (one to two antipsychotic prescriptions; OR 1.22, 95% CI: 1.01 to 1.48) as well as long-term use (>30 prescriptions; OR 1.45, 95% CI 1.19 to 1.76) were associated with an increased risk of CKD. Both use of SGAs with mild and high risk of metabolic disturbances was associated with increased risk of CKD (OR 1.21, 95% CI: 1.06 to 1.39 and OR 1.36, 95% CI: 1.11 to 1.68, respectively). Recent use of non-steroidal anti-inflammatory drugs, prior use of lithium, hypertension or prior acute kidney injury were not clearly associated with development of CKD connected to SGA exposure. The highest risk of CKD was found for clozapine (OR 1.81, 95% CI: 1.22 to 2.69).
conclusionUse of SGA is associated with a small-to-moderately increased risk of incident CKD. All investigated SGAs, except for aripiprazole, were associated with an increased risk of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.